Prospective Research in Memory Clinics (PRIME)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00297271
Recruitment Status : Completed
First Posted : February 28, 2006
Last Update Posted : December 2, 2013
Information provided by (Responsible Party):
Janssen-Cilag Pty Ltd

February 24, 2006
February 28, 2006
December 2, 2013
August 2005
August 2011   (Final data collection date for primary outcome measure)
The primary objective of the study is to analyse the epidemiology and treatment outcomes of mild cognitive impairment and dementia under conditions of routine clinical practice [ Time Frame: 6 months, 12 months and 36 months ]
Not Provided
Complete list of historical versions of study NCT00297271 on Archive Site
  • Change From Baseline in Clinical Dementia Rating Scale (total and overall score) [ Time Frame: Baseline, 3, 6, 12, 24, and 36 months ]
    CDR is a 5-point scale to evaluates the clinical patterns and severity of the patients suspected or diagnosed as dementia in 6 areas: memory, orientation, judgment and problem solving ability, social activity, domestic living and hobbies, and hygiene and dressing up, where 0 = no cognitive impairment, 0.5 = very mild dementia, 1 = mild, 2 = moderate, and 3 = severe. Higher scores indicate worsening.
  • Mini Mental State Examination (total score) [ Time Frame: Baseline, 3, 6, 12, 24 and 36 months ]
    The mini-mental state examination (MMSE) is a brief 30-point questionnaire test that is used or the assessment of dementia patients' cognitive impairment. Evaluation of points are as follows: 24 to 30 = no cognitive impairment, 18 to 23 = mild cognitive impairment, 0 to 17 = severe cognitive impairment. Lower scores indicate worsening.
  • The Alzheimer's Disease Assessment Scale (cognitive total score) [ Time Frame: Baseline, 3, 6, 12, 24 and 36 months ]
    Alzheimer's Disease Assessment Scale is consists of 11 items, which assess memory, language and praxis, and can be administered independently of the non-cognitive portion. The total score ranges between 0 (best) and 70 (worst), with eight of the eleven items scoring between 0 (no impairment) and 5 (most impairment), and three of the items scoring from 0 to 8 (orientation questions), 0 to 10 (word recall) and 0 to 12 (word recognition). Higher scores indicate worsening
  • The Clock Drawing Test (total score) [ Time Frame: Baseline, 3, 6, 12, 24 and 36 months ]
    The Clock Drawing Test is a simple and reliable measure of visuospatial ability. The test requires the participant to draw the face of a clock reading ten minutes after eleven, and the rater scores the result from 10 (best) to 1 (worst). Lower scores indicate worsening.
  • Frontal Assessment Battery (total score) [ Time Frame: Baseline, 3, 6, 12, 24 and 36 months ]
    Frontal Assessment Battery is a short, simple testing for frontal lobe function that explores six domains of frontal lobe activity; conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy. It takes approximately 10 minutes to administer.
  • Functional Autonomy Measurement System (total score and subscores) [ Time Frame: Baseline, 3, 6, 12, 24 and 36 months ]
    Functional Autonomy Measurement System is a 29-item scale developed according to the WHO classification of disabilities. It measures functional ability in five areas: activities of daily living (ADL), mobility, communication, mental functions and instrumental activities of daily living (IADL). For each item, the disability is scored on a 5-point scale: 0 (independent), -0.5 (with difficulty), -1 (needs supervision), -2 (needs help), -3 (dependent). A disability score (up to -87) can be calculated, together with sub-scores for each dimension.
  • Neuropsychiatric Inventory (total score, total distress to caregivers score, and total number of behaviors) [ Time Frame: Baseline, 3, 6, 12, 24 and 36 months ]
    The neuropsychiatric inventory is used to characterize the neuropsychiatric symptom profiles in a variety of neurological diseases. Categories include symptoms like delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability, apathy, Night-time behaviour, appetite and eating, and aberrant motor activity. For each symptom, responder has to indicate "yes", if the symptom has been present since a month. The responder then rate the severity of the symptom on a 3-point scale for which scores range from "1 = Mild (noticeable, but not a significant change)" to "3 = Severe (very marked or prominent; a dramatic change)" and also rate the distress experienced due to the symptom on a 6-point scale for which scores range from "0 = Not distressing at all" to "5 = Extreme or very severe (extremely distressing, unable to cope with)". Higher scores indicate more behavioural disturbance.
  • Zarit caregiver burden interview (total score) [ Time Frame: Baseline, 3, 6, 12, 24 and 36 months ]
    Zarit caregiver burden scale is used to measure caregiver burden as it relates to time, developmental comparison with peers, physical health, social relationships, and emotional health. It has 22 item and each question is scored on a 5-point Likert scale ranging from 0 = never present to 4 = nearly always present. The sum of the total scores of the 22-items is calculated in the range from 0 (low burden) to 88 (high burden). Higher scores indicate worsening.
  • Resource Utilization [ Time Frame: Every month up to 36 months ]
    Resource utilization questionnaire will be completed at the end of each calendar month by participant/caregiver.
Not Provided
Not Provided
Not Provided
Prospective Research in Memory Clinics (PRIME)
Prospective Research in Memory Clinics (PRIME)
The purpose of the PRIME Study is to examine the current management and outcomes of patients with mild cognitive impairment or dementia. Approximately 4500 patients will be enrolled in this disease registry across 12 sites in Australia. Clinical, treatment, health status and economic data will be acquired over 3 years. The study will identify the relationships among demographic variables, prognostic features, geographic setting, treatment options and clinical, economic and health status (activities of daily living and caregiver impact) outcomes.
A complete record of patient care will be collected to provide detailed information on the management and outcome of mild cognitive impairment and dementia and the profile of patients at participating sites. The data will be used to build models looking at the effect of management of these conditions on principal clinical events, health status and economic outcomes. This will provide the foundation for subsequent objective and prospective evaluation of evidence-based strategies for the optimal treatment of mild cognitive impairment and dementia in Australia. This study is not prescriptive, but will instead examine the influence of a whole range of routinely used management strategies on clinical and economic outcomes among mild cognitive impaired and dementia patients in Australia. This 'practice based' approach is increasingly widely used and is a useful tool for elucidating the relative effectiveness of different management strategies and for exploring relationships between patient characteristics, treatment and outcomes. Observational study - no study drug administered.
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Consenting patients with mild cognitrive impairement or dementia recruited at 12 participating sites accross Australia.
  • Dementia
  • Mild Cognitive Impairment
Other: Current treatment practice of each participating physician
Patients will be observed for the evaluation of current management strategies.
Mild cognitive impairment or dementia
Patients with mild cognitive impairment or dementia.
Intervention: Other: Current treatment practice of each participating physician
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2011
August 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of dementia under the DSM-IV criteria, or of Mild Cognitive Impairment, using the Peterson Criteria
  • Living in the community (home, apartment or collective housing with nursing care available for less than 40 hours per week)
  • Patient able to provide written informed consent, or provision of written informed consent by a legal guardian/proxy
  • Availability of a caregiver willing to provide consent for required components of the study
  • Fluent in English
  • May be participating in a Phase IV or other post-marketing follow up study of an approved product for treatment of dementia

Exclusion Criteria:

  • No concomitant life-threatening illness (a condition which is likely to interfere with the patient's ability to complete the study)
  • Not unwilling or unable to complete the study
  • Not concurrently participating in a clinical trial of an investigational drug (phase I, II or III)
  • Unwillingness of patient or legal guardian / proxy to provide written informed consent
  • Unwillingness of caregiver to provide written informed consent
  • For patients with diagnosis of mild cognitive impairment: current or previous treatment with any cholinesterase or memantine
Sexes Eligible for Study: All
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
United Kingdom
GALDEM4007 ( Other Identifier: Janssen-Cilag Pty Ltd, Australia )
Not Provided
Not Provided
Janssen-Cilag Pty Ltd
Janssen-Cilag Pty Ltd
Not Provided
Study Director: Janssen-Cilag Pty Ltd Clinical Trial Janssen-Cilag Pty Ltd
Janssen-Cilag Pty Ltd
November 2013